Intelligence · Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe — grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring ≤24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months — use filters for patent-cliff planning.
-
US 7635486
Recombinant lipidated PsaA protein, methods of preparation and use
granted -
US 7635485
Method of accelerated vaccination against Ebola viruses
granted -
US 7632659
Use of Shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo
granted -
US 7632510
Methods of inducing flavivirus immune responses through the administration of recombinant flaviviruses comprising an engineered japanese encephalitis virus signal sequence
granted -
US 7632508
Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
granted -
US 7625736
Methods for preparing immunogenic conjugates
granted -
US 7625571
Transformed bacteria producing CS6 antigens as vaccines
granted -
US 7622113
Monoclonal antibodies that bind or neutralize dengue virus
granted -
US 7622123
Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
granted -
US 7622272
Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology
granted -
US 7618632
Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
granted -
US 7618623
Hybrid adeno-retroviral vector for the transfection of cells
granted -
US 7619057
MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
granted -
US 7615227
Use of CpG oligodeoxynucleotides to induce angiogenesis
granted -
US 7612093
Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy
granted -
US 7612044
Melanoma antigens and their use in diagnostic and therapeutic methods
granted -
US 7608422
Simian immunodeficiency virus (SIV) molecular clone encoding mutant gag gene lacking inhibitory/instability regions
granted -
US 7605127
Truncated hepatocyte growth factor variant protein HGF/NK2
granted -
US 7604811
Oral-intestinal vaccines against diseases caused by enteropathic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
granted -
US 7605125
DNA-binding polyamide drug conjugates
granted -
US 7601114
Apparatus and method for enhancing tissue repair in mammals
granted -
US 7598225
Generation of immune response to prostate-specific antigen (PSA)
granted -
US 7598077
Compositions and methods for enhancing differential expression
granted -
US 7595191
Isolation and purification of P. falciparum merozoite protein-142 vaccine
granted -
US 7589181
Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
granted -
US 7588703
Microencapsulation system and method
granted -
US 7585667
Negative strand RNA virus replicon
granted -
US 7585841
Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src
granted -
US 7582430
Immunoliposome-nucleic acid amplification (ILNAA) assay
granted -
US 7582680
Methods and compositions for treating mammalian spinal cord injuries
granted -
US 7579006
Method of treating immune pathologies with low dose estrogen
granted -
US 7579453
Variants of human taste receptor genes
granted -
US 7575742
Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
granted -
US 7576050
GLP-1 exendin-4 peptide analogs and uses thereof
granted -
US 7572771
Multi-domain amphipathic helical peptides and methods of their use
granted -
US 7574340
Small molecules and a pharmacophore model for inhibition of botulinum toxin and methods of making and using thereof
granted -
US 7572828
Identification of anti-HIV compounds inhibiting virus assembly and binding of nucleocapsid protein to nucleic acid
granted -
US 7572449
Vaccine against Yersinia comprising one or two antibodies, one specific for Yersinia pestis F1-antigen and the other one for Yersinia pestis V-antigen
granted -
US 7572887
Gene expressed in prostate cancer, methods and use thereof
granted -
US 7569673
Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors
granted -
US 7566465
Artemisinins in the clinical and veterinary management of kinetoplastid infections
granted -
US 7566451
Human immunodeficiency virus-neutralizing human antibodies with improved breadth and potency
granted -
US 7566540
Monoclonal antibody which agglutinates E. coli having the CS4-CFA/I family protein
granted -
US 7563883
Recombinant P. falciparum merozoite protein-142 vaccine
granted -
US 7563459
Methods and compositions for regenerating tissue
granted -
US 7563596
Method of modulating tissue growth using Frzb protein
granted -
US 7563766
Methods and compositions for the promotion of a hair growth utilizing actin binding peptides
granted -
US 7560118
Attenuated dengue virus comprising mutations in the NS3 gene
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory